Metformin causes a futile intestinal–hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state

OBJECTIVE: Metformin, the first line drug for treatment of type 2 diabetes, suppresses hepatic gluconeogenesis and reduces body weight in patients, the latter by an unknown mechanism. METHODS: Mice on a high fat diet were continuously fed metformin in a therapeutically relevant dose, mimicking a ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Schommers, Philipp, Thurau, Anna, Bultmann-Mellin, Insa, Guschlbauer, Maria, Klatt, Andreas R., Rozman, Jan, Klingenspor, Martin, de Angelis, Martin Hrabe, Alber, Jens, Gründemann, Dirk, Sterner-Kock, Anja, Wiesner, Rudolf J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485244/
https://www.ncbi.nlm.nih.gov/pubmed/28702329
http://dx.doi.org/10.1016/j.molmet.2017.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485244/
https://www.ncbi.nlm.nih.gov/pubmed/28702329
http://dx.doi.org/10.1016/j.molmet.2017.05.002

Ejemplares similares